A petition asking for cancer drug Keytruda to be funded for early-stage breast cancer has received more than 17,000 signatures. Triple negative breast cancer is a sub-type of breast cancer which lacks the receptors for hormones or HER2 protein found in other breast cancers, affecting about 10% of New Zealand woman diagnosed. Keytruda is funded for early-stage triple negative breast cancer in more than 40 countries, including Australia, the United Kingdom and Canada. "I mean, yes, I'm alive and I'm grateful. In 2007, Wikeepa was among a group who took a case to the High Court to get Herceptin funded for HER2-positive breast cancer, helping about 600 women each year.